Cannabis-based medicines will be available at SUS in São Paulo

Tempo de Leitura: < 1 minutos

This past Tuesday (31), the governor of São Paulo, Tarcísio de Freitas, validated the bill that guarantees the delivery of cannabis-based drugs by the SUS in the State. The new law allows qualified health professionals to prescribe this therapy to patients with specific diagnoses such as autism, epilepsy and Alzheimer’s. Thus, the beginning of treatment of these diseases becomes faster and less bureaucratic, because previously the drugs were only released through legal approval.

2022 was the year that most studied cannabis in the world

Cannabidiol is one of the main active compounds extracted from the Cannabis plant, known for its biological activities, including anti-inflammatory, antioxidant, anticonvulsant, and ansiolytic properties, and is used to manage pain, inflammation and swelling associated with lesions.

Its therapeutic potential has been evaluated in pathologies associated with oxidative stress and inflammation. That is why cannabis has been widely used as a palliative treatment to control pain. However, due to the presence of tetrahydrocannabinol, there are several concerns about its clinical use, facing resistance at many levels (clinical, social, and political).

Clinical practice

The clinical use of cannabidiol has been studied against the background of diseases with an inflammatory profile such as cancer, neurodegenerative processes and autoimmune diseases. Several clinical studies have been and continue to be conducted to understand the safety and applicability of cannabis in such conditions. To date, studies have suggested that cannabidiol is well tolerated, and its main adverse effect is diarrhoea.


Study suggestion: Once
and for all: endocannabinoid system and eating behavior – Science Play

Watch the video on Science Play with Paula Leite:
Cannabis and intestinal microbiota: a new era of discoveries

Article: Luz-Veiga M, Azevedo-Silva J, Fernandes JC. Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies. Pharmaceuticals. 2023; 16(2):155.

Nos siga nas redes sociais

Mais lidas

Próximos eventos

Artigos relacionados